Fulvestrant, a selective estrogen receptor inhibitor, has been approved for the treatment of breast cancer by inhibiting ERα signaling and suppressing the immune response.26 To explain the underlying mechanism by which PSRC1 OE inhibited FMO3, we used Fulvestrant to treat the transfected cells. This evidence concerns the gene PSRC1 and breast cancer.